The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab

Dermatology

Volumn 221, Issue SUPPL. 1, 2010, Pages 43-47

  Papoutsaki, M ^a   Talamonti, M ^b   Giunta, A ^b   Costanzo, A ^b   Ruzzetti, M ^b   Teoli, M ^b   Chimenti, S ^b  

^a ANDREAS SYGROS HOSPITAL   (Greece)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Analytical methodology; Infliximab; Long term data; Plaque type psoriasis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; DRUG EFFICACY; DYSPNEA; FEMALE; HUMAN; LARYNX DISORDER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; TREATMENT OUTCOME; LONGITUDINAL STUDY; MIDDLE AGED; PSORIASIS; STATISTICAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DATA INTERPRETATION, STATISTICAL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 77956037959     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316184     Document Type: Article

References (22)

1. Griffiths CEM, Barker J: Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
2. Christophers E: Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320.
3. Lebwohl M: Psoriasis. Lancet 2003; 361: 1197-1204.
4. Schon MP, Boehncke WH: Psoriasis. N Engl J Med 2005; 352: 1899-1912.
5. Gladman DD, Brockbank J: Psoriatic arthritis. Expert Opin Investig Drugs 2000; 9: 1511-1522.
6. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD: Elevated tumor necrosis factor- (TNF- ) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-151.
7. Höhler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C, Meyer zum Büschenfelde KH, Märker-Hermann E: A TNF- promoter polymorphism is associated with juvenile onset of psoriasis and psoriatic arthritis. J Invest Dermatol 1997; 109: 562-565.
8. Partsch G, Steiner G, Leeb BF, Dunky A, Bröll H, Smolen JS: Highly increased levels of tumor necrosis factor- and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518-523.
9. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ: Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25: 1544-1552.
10. Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB: Macrophage-derived cytokine and nuclear factor- B p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000; 43: 1244-1256.
11. Partsch G, Wagner E, Leeb BF, Dunky A, Steiner G, Smolen JS: Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 1998; 25: 105-110.
12. Boss JD, de Rie MA: The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20: 40-46.
13. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A: Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542.
14. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE: Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
15. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB: A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 1-15.
16. Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A: Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726.
17. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K: Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
18. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators: Efficacy and safety of ustekinumab, a human interleukin- 12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684.
19. Papp KA, Fonjallaz P, Casset-Semanaz F, Krueger JG, Wittkowski KM: Analytical approaches to reporting long-term clinical trial data. Curr Med Res Opin 2008; 24: 2001-2008.
20. Gordon KB, Tyring S, Gu Y, Okun MM: Psoriasis patients treated continuously with adalimumab: efficacy and safety results from months 12 to 18 (abstract). J Am Acad Dermatol 2008; 58:AB129 (abstract P2654).
21. Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Wain M, Barker JN: Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 2006; 155: 160-169.
22. ICH Expert Working Group: ICH harmonised tripartite guideline. Statistical principles for clinical trials. 5 February 1998.